HCA’s lobby is now open for walk-in customer service. Learn about customer service options.
Prescription drug price transparency
On this page
Want to stay up-to-date on prescription drug price transparency?
Reporting entity resources (carriers, manufacturers, PBMs, PSAOs)
The following resources are for reporting entities who may need assistance.
The excel templates below are available as an aid if you are hand-keying data for submissions to the Drug Price Transparency program. These workbooks are programmed with simple rules that will help you avoid some common errors that can occur.
Important note about Excel version: We recommend using Microsoft Excel 2016 or earlier for the submission guides. Using Microsoft Excel 2019 can cause formatting issues when saving as a CSV file.
All
- Reporting entity registration form
- Reporting entity extension request form
- Reporting entity data resubmission form
When using this form:- You must resubmit the entire report.
- The report name must match previously submitted report name.
- Data submission FAQ (updated 12/1/2021)
Carriers
- Data submission guide v3.0 - draft (carrier feedback due by May 5, 2022)
- Change summary
Report year 2020 (due date: December 1, 2021)
- Data submission guide
- Cost utilization template
- Premium impact template
- Specialty drug list template
Report years 2018 - 2019
- Data submission guide
- Cost utilization template
- Premium impact template
- Specialty drug list template
Manufacturers
Report year 2022
Pharmacy Benefit Managers (PBMs)
Report year 2020 (due date: March 1, 2022)
Report years 2018-2019
Pharmacy Services Administrative Organizations (PSAOs)
- Data submission guide v3.0 - draft (PSAO feedback due by May 5, 2022)
- Change summary
Report year 2020 (due date: December 1, 2021)
- Data submission guide
- Pharmacy benefit manager contracted rates template
- Pharmacy benefit manager year-over-year rate change template
- Pharmacy contracted rates template
- Pharmacy year-over-year rate change template
Stakeholder meetings
At each meeting, HCA will give a short overview of Chapter 43.71C RCW then use the majority of time to take questions and hear concerns from stakeholders. We will focus on a different supplier in each meeting. The public is invited to participate in any of the meetings.
Meeting schedule
Date and time | Meeting type | Materials |
---|---|---|
July 28, 2021 | PBM listening session | |
July 22, 2021 | Manufacturer listening session | |
July 6, 2021 | Carrier listening session | |
April 29, 2020 |
Pharmacy benefit manager / pharmacy service administrative organization reporting Webinar only, no in person meeting due to COVID-19 |
|
April 1, 2020 |
Issuer / carrier reporting Webinar only, no in person meeting due to COVID-19 |
Updated slide deck |
February 26, 2020 | Manufacturer reporting |
Background
In 2019, the Washington State Legislature passed Engrossed Second Substitute House Bill into law. This law requires issuers of health insurance, pharmacy benefit managers (PBMs), manufacturers, and pharmacy service administrative organizations (PSAOs) to submit data to the Health Care Authority (HCA). The purpose is to create an annual report on how prescription drugs affect health care costs. The law also requires pharmaceutical manufacturers to submit data to HCA relating the new drug applications (NDA).
Reports
Annual reports created by HCA to detail the current state of the program as the agency begins to receive drug pricing and cost data.
Contact
Program questions and information
Email: HCA Drug Price Transparency - general inquiry
Technical data related questions, or any questions regarding the data submission process
Email: HCA Drug Price Transparency - tech support
Protections for insurance consumers and insurance industry oversight
Contact: Washington State Office of the Insurance Commissioner (OIC)